Hostname: page-component-7bb8b95d7b-s9k8s Total loading time: 0 Render date: 2024-09-21T01:20:24.789Z Has data issue: false hasContentIssue false
  • English
  • Français

Dopamine Agonists in Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

Donald B. Calne ,
Keith Burton ,
Jeff Beckman  and
W.R. Wayne Martin
Keith Burton
Affiliation:
Division of Neurology. Department of Medicine, University of British Columbia, Health Sciences Centre Hospital, 2211 Westbrook Mall, Vancouver
Jeff Beckman
Affiliation:
Division of Neurology. Department of Medicine, University of British Columbia, Health Sciences Centre Hospital, 2211 Westbrook Mall, Vancouver
W.R. Wayne Martin
Affiliation:
Division of Neurology. Department of Medicine, University of British Columbia, Health Sciences Centre Hospital, 2211 Westbrook Mall, Vancouver
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Dopamine agonists have yielded two important advances to our understanding of the basal ganglia – they have facilitated the subdivision of different classes of dopamine receptors, and they have established the fact that important dopaminergic effects can be achieved by activation of dopamine receptors in a manner that is unrelated to anoxal impulse traffic in dopaminergic neurons – a phenomenon similar in its diffuse, slow, characteristics to an endocrine effect.

The tangible clinical benefit of dopamine agonists has been evident in patients with prominent dyskinesia or wearing off reactions. It is possible that earlier use of agonists, in low doses combined with similarly low doses of levodopa, may improve the long term treatment of Parkinson’s disease, but as yet there is no firm evidence.

In the future, we can expect to see agonists with more prolonged effects, deriving from the formation of active metabolites. We can also hope to gain further insight into the correlations between the various animal models of dopaminomimetic activity, and specific aspects of drug efficacy and toxicity in parkinsonian patients. Such information should allow the design of improved pharmacotherapy.

Type
7. Treatment of Parkinson’s Disease
Information
Canadian Journal of Neurological Sciences , Volume 11 , Issue S1: Current Concepts and Controversies in Parkinson’s Disease , February 1984 , pp. 221 - 224
Copyright
Copyright © Canadian Neurological Sciences Federation 1984

References

Calne, DB, Teychenne, PF, Claveria, LE, Eastman, R, Greenacre, JK, Petrie, A(1974 Bromocriptine in parkinsonism. Br. Med. J., 4:442–444.CrossRefGoogle Scholar
Calne, DB, Langston, JW (1983) The aetiology of Parkinson’s disease: An hypothesis. Lancet, (in press).CrossRefGoogle Scholar
Calne, DB, Williams, AC, Neophytides, A, Plotkin, C, Nutt, JG, Teychenne, PF (1978) Long-term treatment of parkinsonism with bromocriptine. Lancet 1:735–738.CrossRefGoogle ScholarPubMed
Cotzias, GC, Papavasiliou, PS, Tolosa, ES, Mendez, JS, Bell-Midura, M (1976) Treatment of Parkinson’s disease with aporphines. New Eng. J. Med. 294(11): 567–572.CrossRefGoogle ScholarPubMed
Enz, A (1981) Biphasic influence of a alpha-aminoergoline, CU 32–085, on striatal dopamine synthesis and turnover in vivo in the rat. Life Sci. 29: 2227–2234.CrossRefGoogle Scholar
Fluckiger, E, Briner, U, Enz, A, Markstein, R, Vigouret, JM (1983) Dopaminergic ergot compounds: An overview. In: Calne, et al. (Eds.), Lisuride and Other Dopamine Agonists. Raven Press, New York 1:9.Google Scholar
Grigoriadis, D, Seeman, P (1984) The dopamine/neuroleptic receptor. Can. J. Neurol. Sci. (in press).CrossRefGoogle Scholar
Kebabian, JW, Calne, DB (1979) Multiple receptor mechanisms for dopamine. Nature 277: 93–96.CrossRefGoogle Scholar
Kebabian, JW, Greengard, P (1971) Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science 174: 1346–1349.CrossRefGoogle ScholarPubMed
Lang, AE, Sheehy, MP, Quinn, NP, Brincat, S, Marsden, CD, Parkes, D (1983) Lisuride and pergolide in Parkinson’s disease. In: Fahn, S, Calne, DB, Shoulson, I (Eds.), Advances in Neurology, Volume 37. Raven Press, New York109–120.Google Scholar
Leff, SE, Creese, I (1983) Dopamine receptors re-explained. Trends Pharm. Sci. November: 463–467.CrossRefGoogle Scholar
Lemberger, L, Crabtree, RE (1979) Pharmacologic effects in man of a potent, long acting dopamine receptoragonist. Science 205:1151–1153.CrossRefGoogle Scholar
Lieberman, AN, Gopinathan, G, Hassouri, H, Neophytides, A, Goldstein, M (1984) Should dopamine agonists be given early or late? A review of 9 years of experience with bromocriptine. Can. J. Neurol. Sci. (in press).CrossRefGoogle Scholar
Schwab, RS, England, AC, Poskanzer, DC, Young, RR (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208: 1168–1170.CrossRefGoogle ScholarPubMed
Seeman, P (1980) Brain dopamine receptors. Pharm. Rev. 32: 229–313.Google ScholarPubMed
Spano, PF, Govoni, S, Trabucchi, M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. In: Roberts, PJ, Woodruff, GN, Iversen, LL (Eds.), Advances in Biochemical Psychopharmocology, Volume 19. Raven Press, New York155–165.Google Scholar
Stern, GM, Lees, AJ (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. In: Fahn, S, Calne, DB, Shoulson, I (Eds.), Advances in Neurology, Volume 37. Raven Press. New York17–21.Google Scholar
Stoof, JC, Kebabian, JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366–368.CrossRefGoogle ScholarPubMed
Teychenne, PF.Bergsrud, D, Racy, A, Elton, RL, Vern, B (1982) Bromocriptine: Low-dose therapy in Parkinson’s disease. Neurology (NY) 32: 577–583.CrossRefGoogle Scholar
Teychenne, PF.Jones, EA, Ishak, KG, Calne, DB (1979) Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: a dopaminergic ergot derivative. Gastroenterology 76: 575–583.CrossRefGoogle ScholarPubMed
Wachtel, H (1983) Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to Lisuride. In: Calne, et al. (Eds.), Lisuride and Other Dopamine Agonists. Raven Press, New York109–125.Google Scholar